2.4
Tomografia por Emissão de Pósitrons
A tomografia por emissão de pósitrons (PET) é uma técnica de exames por imagem médica que envolve radiofármacos, substâncias que emitem radiação de cu…
A tomografia por emissão de pósitrons, ou PET, é uma técnica de imagem médica baseada em radiotraçador comumente usada para detecção de tumores, determinando a extensão das metástases, avaliando doenças cardíacas como suprimento sanguíneo prejudicado e estudando a atividade neural no cérebro.
Para realizar uma tomografia por emissão de pósitrons, o paciente é mais frequentemente injetado com um marcador radioativo, uma molécula biológica ligada a um isótopo emissor de pósitrons, como carbono-11, oxigênio-15 ou flúor-18.
Uma vez no corpo, esses radiotraçadores se acumulam dentro do tecido ou das células onde têm maior afinidade. Por exemplo, a fluorodesoxiglicose ou FDG se acumula mais nos tumores devido à sua maior atividade metabólica.
O flúor radioativo instável decai, emitindo pósitrons - a antipartícula de elétrons carregada positivamente. Os pósitrons se combinam com elétrons próximos, resultando em uma reação de aniquilação e emitem dois fótons de energia de 511 keV em direções opostas.
O detector PET coleta milhões desses eventos de aniquilação e, usando algoritmos de computação complexos, reconstrói as imagens da distribuição do traçador na área em estudo.
View the full transcript and gain access to JoVE Core videos
Q1: What is positron emission tomography and what are its main clinical applications?
Positron emission tomography (PET) is a radiotracer-based medical imaging technique that detects positron-emitting isotopes to visualize tissue function. PET is widely used to diagnose tumor detection, determine cancer metastases, evaluate heart disease and impaired blood supply, study brain neural activity, and assess infections, bone disease, and thyroid conditions. Unlike static imaging, PET reveals physiologic activity including nutrient metabolism and blood flow.
Q2: How do radiotracers work in a PET scan?
Radiotracers are biological molecules bound to positron-emitting isotopes like fluorine-18 or carbon-11. When injected into the patient, they accumulate in tissues with higher affinity, such as tumors with elevated metabolic activity. For example, fluorodeoxyglucose (FDG) concentrates in cancer cells because they metabolize glucose differently than normal tissue, allowing PET to detect abnormal regions.
Q3: What happens during the positron annihilation process in PET imaging?
Radioactive fluorine decays and emits positrons, which are positively charged antiparticles of electrons. When positrons combine with nearby electrons, an annihilation reaction occurs, emitting two photons of 511 keV energy in opposite directions. PET detectors collect millions of these annihilation events and use complex computing algorithms to reconstruct detailed images of tracer distribution in the body.
Q4: How is a radiotracer prepared for use in PET scanning?
Positron-emitting radioisotopes are produced in a cyclotron through proton bombardment. For example, fluorine-18 is created by bombarding oxygen-18, then incorporated into a glucose analog called fludeoxyglucose (FDG). This tagged compound is then injected intravenously or inhaled as a gas, allowing the scanner to track how tissues utilize the radiotracer.
Q5: How does PET imaging differ from CT and MRI scans?
PET scans reveal physiologic activity, including nutrient metabolism and blood flow, showing how organs function. In contrast, computed tomography and magnetic resonance imaging produce static anatomical images. PET is now typically performed alongside computed tomography or magnetic resonance imaging to provide comprehensive data visualization and improve diagnostic interpretation.
Q6: What information can PET imaging reveal about brain function?
PET can locate regions in the brain that become active during specific activities such as speaking or closing the eyes. By tracking radiotracer accumulation in different brain areas, PET reveals neural activity patterns and can detect brain abnormalities. This functional imaging capability makes PET valuable for studying cognitive processes and diagnosing neurological conditions.
Q7: What are the advantages of using different radiotracers in PET imaging?
Different radiotracers target specific tissues based on their biological properties. For example, radioactive iodine monitors thyroid function, while radioactive gallium detects cancer. Fluorodeoxyglucose (FDG) reveals glucose metabolism differences between normal and abnormal tissues. This versatility allows PET to diagnose diverse conditions by selecting radiotracers that accumulate in the target organ or pathology.